title: [Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber].
abstract: Antiplatelet therapy by acetylsalicylic acid (aspirin) provided pivotal advances in the prevention and treatment of organovascular (cardiovascular, cerebrovascular, extremitovascular, renovascular, genitovascular, mesenteriovascular, bronchopulmovascular, oculovascular, otovascular and other) arterial ischemic diseases. Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects. Document (Guidelines) of the Angiology Section of the Slovak Medical Chamber (AS SMS, 2013).
authors.forename: P
authors.initials: P
authors.lastname: Gavornik
authors.forename: A
authors.initials: A
authors.lastname: Dukát
authors.forename: L
authors.initials: L
authors.lastname: Gašpar
mesh_terms: D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D018153:Czech Republic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007511:Ischemia / Q000188:drug therapy; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010979:Platelet Function Tests; D013927:Thrombosis / Q000188:drug therapy; D014652:Vascular Diseases
chemical_list: D015507:Drugs, Investigational; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin